Prior authorization likely required for non-routine services

Services outside the policy's covered indications (including procedures listed as unproven) may require review and will typically follow the plan's prior authorization process. Confirm prior authorization requirements with the member's plan.

Prior authorization likely required for implantable neurostimulator procedures

Implantable neurostimulation devices (e.g., occipital nerve stimulation, spinal cord stimulation, SPG stimulators) carry device-related risks and generally require documentation of medical necessity, a confirming temporary trial response, and evidence of failed conservative therapies; check payer-specific prior authorization rules.

State-specific policy applicability

This medical policy applies only to the state of Pennsylvania; confirm that the member and requested service are in Pennsylvania and refer to Pennsylvania Code Title 55, Chapter 1101 for exceptions.

Evidence limitations and need for conservative therapy trials

The policy notes insufficient high-quality evidence for many surgical and ablative procedures (few RCTs, small samples, retrospective designs). Clinicians should document prior conservative treatments and objective response to diagnostic blocks when considering invasive interventions.

Positive diagnostic block as predictor of surgical/RFA response

A definite positive response to a prior diagnostic nerve block (commonly defined as ≥ 50% pain relief) is associated with a greater likelihood of success after radiofrequency ablation or surgical procedures; document prior block response in the record.

Monitor and record outcome measures and follow-up

Document baseline and follow-up outcome measures commonly reported in studies (e.g., VAS/NRS pain scores, headache days per month, MIDAS, MHI, MSQ) to support clinical decisions and claims.

Document trial response for ONS

For permanent occipital nerve stimulation implantation, document a positive response to a temporary trial—commonly defined in the literature and this policy as at least a 50% reduction in pain during the trial period.

• Trial response threshold: ≥ 50% reduction in pain during temporary trial

Denial risk for unsupported indications

Coverage may be denied when neurostimulation is requested for indications lacking adequate high-quality evidence (for example, non‑refractory headache types) or when documentation of prior therapies and trial response is absent.

Diagnostic blockade preceding RFN

Diagnostic blockade of the occipital nerves should precede radiofrequency neurotomy (RFN) to identify the pain generator prior to offering RFN.

Imaging before RFN

Before performing RFN of the occipital nerves, rule out other possible etiologies with MRI and/or CT imaging; imaging is used to exclude other causes though it is not diagnostic for occipital neuralgia.

Use of International Headache Society diagnostic criteria

Use the International Headache Society diagnostic criteria for occipital neuralgia as standard practice for patient selection.

Special arrangements for certain neuromodulation procedures (per NICE guidance)

Certain neuromodulation or interventional procedures (e.g., transcutaneous stimulation of the supraorbital nerve, ONS, SPG implantation) should be used only with special arrangements for clinical governance, consent, audit or research and outcome data collection, consistent with NICE recommendations.

Use policy to interpret benefit plans

Before applying this policy, check federal, state, or contractual benefit plan requirements as they may differ and govern in the event of conflict; document compliance with applicable requirements.

Use of external clinical tools

UnitedHealthcare may use third-party clinical tools (for example, InterQual) to assist in administering benefits; providers should expect these tools may inform utilization management decisions.